



Press Release

FOR IMMEDIATE RELEASE

Contacts:

Dr. Wayne Danter, President & CSO
519-858-5157
wdanter@criticaloutcome.com

Michael Barr, Director of Marketing &
Business Development
519-858-5157
mbarr@criticaloutcome.com

CRITICAL OUTCOME TECHNOLOGIES INC. APPOINTS NEW DIRECTOR

London, Ontario (February 20, 2007): Critical Outcome Technologies Inc. (TSX Venture: COT), is pleased to announce the appointment of Mr. John Drake to its Board of Directors.

Mr. Drake is the Chief Executive Officer of Critical Outcome Technologies Inc. He is also the President and Founding Partner of Drake Goodwin Corporation, a London, Ontario based investment firm with diverse interests in financial services, real estate development and manufacturing. Mr. Drake is also Chairman of the DGM Bank & Trust Inc. of Barbados. Mr. Drake received a B.A. and L.L.B. from the University of Western Ontario.

“We are very pleased with the appointment of John Drake as a Director,” said Dr. Wayne Danter, President and Chief Scientific Officer. “With his experience, networks and commitment we believe the appointment will increase our Company profile substantially among the Canadian and United States investment communities and support our Board’s mandate of guiding the strategy of the organization.”

The current Board of Directors now consists of Dr. Wayne Danter, Mr. John Drake, Dr. Rainer Engelhardt, Dr. Kathleen Ferguson, Mr. Dean Gendron, Mr. Mark Hlady and Mr. Bruno Maruzzo.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI’s business is focused on the discovery and pre-clinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development. For more information on COTI, please visit www.criticaloutcome.com.